| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
| Cancer Research | Clinical Cancer Research |
| Cancer Epidemiology Biomarkers & Prevention | Molecular Cancer Therapeutics |
| Molecular Cancer Research | Cell Growth & Differentiation |
Cell Growth & Differentiation, Vol 5, Issue 12 1301-1307, Copyright © 1994 by American Association of Cancer Research
ARTICLES |
A Elbendary, A Berchuck, P Davis, L Havrilesky, RC Bast Jr, JD Iglehart and JR Marks
Department of Obstetrics and Gynecology, Duke University Medical Center, Durham, North Carolina 27710.
Transforming growth factor beta (TGF beta) is an important regulator of cellular proliferation. In normal ovarian epithelial cells, TGF beta acts to inhibit growth. However, in ovarian cancer cell lines, this effect is usually lost. Although the regulatory pathway of TGF beta remains unclear, TGF beta-treated cells arrest late in G1. This inhibition appears to involve blocking of the cyclin-dependent kinase phosphorylation of the retinoblastoma protein. Recently, a general inhibitor of cyclin-dependent kinases, CIP1/WAF1/p21, was identified. Expression of CIP1 is positively regulated by binding of wild-type p53 to a consensus response element upstream of the CIP1 gene. Overexpression of the CIP1 protein causes growth suppression, analogous to TGF beta and wild-type p53. We have examined the induction of CIP1 by TGF beta 1 in ovarian cancer cell lines that have been previously characterized for their proliferative response to TGF beta 1. OVCA420, a cell line that is dramatically growth inhibited by TGF beta 1, significantly induced CIP1 expression in response to TGF beta 1. CIP1 induction was accompanied by a decrease in cdk2 kinase activity and cdk2 protein levels. In three other cell lines that respond weakly to TGF beta 1, CIP1 expression was not induced. To determine if TGF beta 1 induction occurs via p53, regulation of p53 RNA and protein was examined. No differences in p53 transcription, steady-state protein level, de novo synthesis, phosphorylation, or subcellular accumulation were noted. Furthermore, TGF beta 1 could not induce transcription from a consensus p53 DNA binding site in the TGF beta 1-response cell line.(ABSTRACT TRUNCATED AT 250 WORDS)
This article has been cited by other articles:
 |
|
 |
|
  Y. Song, C. Zhao, L. Dong, M. Fu, L. Xue, Z. Huang, T. Tong, Z. Zhou, A. Chen, Z. Yang, et al. Overexpression of cyclin B1 in human esophageal squamous cell carcinoma cells induces tumor cell invasive growth and metastasis Carcinogenesis, February 1, 2008; 29(2): 307 - 315. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 T. W. Young, D. G. Rosen, F. C. Mei, N. Li, J. Liu, X.-F. Wang, and X. Cheng Up-regulation of Tumor Susceptibility Gene 101 Conveys Poor Prognosis through Suppression of p21 Expression in Ovarian Cancer Clin. Cancer Res., July 1, 2007; 13(13): 3848 - 3854. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. A. Siegenthaler and M. W. Miller Transforming Growth Factor {beta}1 Promotes Cell Cycle Exit through the Cyclin-Dependent Kinase Inhibitor p21 in the Developing Cerebral Cortex J. Neurosci., September 21, 2005; 25(38): 8627 - 8636. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. Wang, N. Sergina, T. C. Ko, J. Gong, and M. G. Brattain Autocrine and Exogenous Transforming Growth Factor {beta} Control Cell Cycle Inhibition through Pathways with Different Sensitivity J. Biol. Chem., September 17, 2004; 279(38): 40237 - 40244. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A. Khanna Concerted effect of transforming growth factor-{beta}, cyclin inhibitor p21, and c-myc on smooth muscle cell proliferation Am J Physiol Heart Circ Physiol, March 1, 2004; 286(3): H1133 - H1140. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
R. A. Gupta, P. Sarraf, J. A. Brockman, S. B. Shappell, L. A. Raftery, T. M. Willson, and R. N. DuBois Peroxisome Proliferator-activated Receptor gamma and Transforming Growth Factor-beta Pathways Inhibit Intestinal Epithelial Cell Growth by Regulating Levels of TSC-22 J. Biol. Chem., February 21, 2003; 278(9): 7431 - 7438. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 L. D. Dunfield, E. J. C. Dwyer, and M. W. Nachtigal TGF{beta}-Induced Smad Signaling Remains Intact in Primary Human Ovarian Cancer Cells Endocrinology, April 1, 2002; 143(4): 1174 - 1181. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. M. Duplan, Y. Theoret, and R. Kenigsberg Antitumor Activity of Fibroblast Growth Factors (FGFs) for Medulloblastoma May Correlate with FGF Receptor Expression and Tumor Variant Clin. Cancer Res., January 1, 2002; 8(1): 246 - 257. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 T. Cheng, H. Shen, N. Rodrigues, S. Stier, and D. T. Scadden Transforming growth factor beta 1 mediates cell-cycle arrest of primitive hematopoietic cells independent of p21Cip1/Waf1 or p27Kip1 Blood, December 15, 2001; 98(13): 3643 - 3649. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 G. Wolf, R. Schroeder, G. Zahner, R. A. K. Stahl, and S. J. Shankland High Glucose-Induced Hypertrophy of Mesangial Cells Requires p27Kip1, an Inhibitor of Cyclin-Dependent Kinases Am. J. Pathol., March 1, 2001; 158(3): 1091 - 1100. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 C.-R. Chen, Y. Kang, and J. Massague Inaugural Article: Defective repression of c-myc in breast cancer cells: A loss at the core of the transforming growth factor beta growth arrest program PNAS, January 30, 2001; 98(3): 992 - 999. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S. J. Shankland and G. Wolf Cell cycle regulatory proteins in renal disease: role in hypertrophy, proliferation, and apoptosis Am J Physiol Renal Physiol, April 1, 2000; 278(4): F515 - F529. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. Baekelandt, R. Holm, C. G. Trope, J. M. Nesland, and G. B. Kristensen Lack of Independent Prognostic Significance of p21 and p27 Expression in Advanced Ovarian Cancer: An Immunohistochemical Study Clin. Cancer Res., October 1, 1999; 5(10): 2848 - 2853. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 H. Drissi, D. Hushka, F. Aslam, Q. Nguyen, E. Buffone, A. Koff, A. J. van Wijnen, J. B. Lian, J. L. Stein, and G. S. Stein The Cell Cycle Regulator p27kip1 Contributes to Growth and Differentiation of Osteoblasts Cancer Res., August 1, 1999; 59(15): 3705 - 3711. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 F. DOCAGNE, O. NICOLE, H. H. MARTI, E. T. MacKENZIE, A. BUISSON, and D. VIVIEN Transforming growth factor-{beta}1 as a regulator of the serpins/t-PA axis in cerebral ischemia FASEB J, August 1, 1999; 13(11): 1315 - 1324. [Abstract] [Full Text]
|
|
|
|
|
|
G. S. Hagopian, G. B. Mills, A. R. Khokhar, R. C. Bast Jr., and Z. H. Siddik Expression of p53 in Cisplatin-resistant Ovarian Cancer Cell Lines: Modulation with the Novel Platinum Analogue (1R, 2R-Diaminocyclohexane)(trans-diacetato)(dichloro)-platinum(IV) Clin. Cancer Res., March 1, 1999; 5(3): 655 - 663. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A. Iavarone and J. Massague E2F and Histone Deacetylase Mediate Transforming Growth Factor beta Repression of cdc25A during Keratinocyte Cell Cycle Arrest Mol. Cell. Biol., January 1, 1999; 19(1): 916 - 922. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
R. A. Steinman, J. Huang, B. Yaroslavskiy, J. P. Goff, E. D. Ball, and A. Nguyen Regulation of p21(WAF1) Expression During Normal Myeloid Differentiation Blood, June 15, 1998; 91(12): 4531 - 4542. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. Pedram, M. Razandi, R.-M. Hu, and E. R. Levin Astrocyte Progression from G1 to S Phase of the Cell Cycle Depends upon Multiple Protein Interaction J. Biol. Chem., May 29, 1998; 273(22): 13966 - 13972. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
B. Tong, H. L. Grimes, T.-Y. Yang, S. E. Bear, Z. Qin, K. Du, W. S. El-Deiry, and P. N. Tsichlis The Gfi-1B Proto-Oncoprotein Represses p21WAF1 and Inhibits Myeloid Cell Differentiation Mol. Cell. Biol., May 1, 1998; 18(5): 2462 - 2473. [Abstract] [Full Text]
|
|
|
|
|
|
H. H. Cha, E. J. Cram, E. C. Wang, A. J. Huang, H. G. Kasler, and G. L. Firestone Glucocorticoids Stimulate p21 Gene Expression by Targeting Multiple Transcriptional Elements within a Steroid Responsive Region of the p21waf1/cip1 Promoter in Rat Hepatoma Cells J. Biol. Chem., January 23, 1998; 273(4): 1998 - 2007. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
W. Poluha, C. M. Schonhoff, K. S. Harrington, M. B. Lachyankar, N. E. Crosbie, D. A. Bulseco, and A. H. Ross A Novel, Nerve Growth Factor-activated Pathway Involving Nitric Oxide, p53, and p21WAF1 Regulates Neuronal Differentiation of PC12 Cells J. Biol. Chem., September 19, 1997; 272(38): 24002 - 24007. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 K. Yamato, T. Koseki, M. Ohguchi, M. Kizaki, Y. Ikeda, and T. Nishihara Activin A Induction of Cell-Cycle Arrest Involves Modulation of Cyclin D2 and p21CIP1/WAF1 in Plasmacytic Cells Mol. Endocrinol., July 1, 1997; 11(8): 1044 - 1052. [Abstract] [Full Text]
|
|
|
|
 |
|
 H Wu, M Wade, L Krall, J Grisham, Y Xiong, and T Van Dyke Targeted in vivo expression of the cyclin-dependent kinase inhibitor p21 halts hepatocyte cell-cycle progression, postnatal liver development and regeneration. Genes & Dev., February 1, 1996; 10(3): 245 - 260. [Abstract] [PDF]
|
|
|
|
|
|
J DeGregori, G Leone, K Ohtani, A Miron, and J R Nevins E2F-1 accumulation bypasses a G1 arrest resulting from the inhibition of G1 cyclin-dependent kinase activity. Genes & Dev., December 1, 1995; 9(23): 2873 - 2887. [Abstract] [PDF]
|
|
|
|
|
|
I Reynisdottir, K Polyak, A Iavarone, and J Massague Kip/Cip and Ink4 Cdk inhibitors cooperate to induce cell cycle arrest in response to TGF-beta. Genes & Dev., August 1, 1995; 9(15): 1831 - 1845. [Abstract] [PDF]
|
|
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
| Cancer Research | Clinical Cancer Research |
| Cancer Epidemiology Biomarkers & Prevention | Molecular Cancer Therapeutics |
| Molecular Cancer Research | Cell Growth & Differentiation |
